Waters Corp. has acquired California-based Halo Labs, provider of specialized imaging technologies to detect, identify and count interfering materials in therapeutic products, such as cell, protein and gene therapies.
By acquiring Halo Labs, Waters will be able to integrate the company’s emerging technology into new and existing large molecule development and QA/QC, giving a key value-add to customers while accelerating growth into analytical and bioprocessing testing for large molecule therapies.
Halo’s Aura platform features a highly differentiated technology that performs full spectrum particle analysis. Its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR-T cells for cell therapy, detecting these translucent process impurities that are currently undetectable by standard methods.
"With the rapid growth of treatments like CAR-T cell therapies, we are investing in the innovation our customers need. Together with our existing Wyatt Technology product lines, this acquisition enhances our leadership position in specialized analytical technologies for emerging biopharma therapies," says Dr. Udit Batra, Waters President and CEO.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!